YD Bio Limited Ordinary Shares YDES

YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.

• GlobeNewswire Inc. 31 ago

  YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

  YD Bio (Nasdaq: YDES), a biotechnology company focused on DNA methylation-based cancer detection and ophthalmologic innovations, announced H1 2026 results showing 315% revenue growth to $846.5 million and net income of $6.7 million. The profitability was primarily driven by a $9.8 million non-cash gain from warrant liability fair value changes. Excluding this adjustment, the company reported an operational net loss of $3.1 million. Revenue growth was fueled by large orders including a $327 million Fetroja order, though gross margins were pressured by lower-margin sales. The company is expanding its laboratory network, advancing exosome manufacturing, and pursuing strategic acquisitions while managing cash burn.

  

• GlobeNewswire Inc. 25 ago

  YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

  YD Bio announced the publication of a peer-reviewed article in Nutrients journal co-authored with physicians from Taiwan's Chronic Disease Healthcare Association and Future Health Institute. The article explores how omega-3, vitamin D3, and vitamin K2 affect cardiovascular, neurological, and skeletal health. This publication expands YD Bio's physician-partnership initiative beyond product development into peer-reviewed research.

  

• GlobeNewswire Inc. 2 jul

  YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

  YD Bio announced that its affiliate EG BioMed US obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania, expanding its CLIA-certified laboratory's authorized operating footprint to 46 U.S. states plus Washington D.C. and Guam. The expansion supports the company's DNA methylation-based early cancer detection operations and broadens patient access to blood-based testing services for various cancers.